Minitran (Glyceryl Trinitrate)

Glyceryl trinitrate is converted in the body to nitric oxide, which activates soluble guanylate cyclase in vascular smooth‑muscle cells. The resulting increase in cyclic guanosine monophosphate (cGMP) causes relaxation of both venous and arterial vessels, lowering preload and afterload, and thereby decreasing myocardial oxygen demand.

The specific dose and patch strength are determined by the prescribing clinician based on the patient’s clinical condition, response, and tolerance. The prescriber selects the appropriate patch size and replacement interval, which may range from 12 to 24 hours, and adjusts therapy according to therapeutic goals.

Safety data for glyceryl trinitrate in pregnancy and lactation are limited, and the product is generally classified as contraindicated or to be used only if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Minitran. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with oral nitrates, the transdermal patch provides steadier plasma levels and avoids first‑pass metabolism, which can improve symptom control and reduce dosing frequency. Relative to beta‑blockers or calcium‑channel blockers, nitrates primarily reduce myocardial oxygen demand through preload reduction, and may be used in combination when monotherapy is insufficient.

Store the patches at room temperature, below 25 °C, in the original sealed packaging. Protect them from moisture, direct sunlight, and extreme temperatures. Keep the product out of reach of children and do not use patches that appear damaged, discolored, or past their expiration date.

The patch is applied to a clean, dry, hair‑free area of the upper torso or upper arm, avoiding areas of irritation or broken skin. After the prescribed wear time, usually 12–24 hours, the patch is removed, folded adhesive side inward, and disposed of safely. A new patch is then applied according to the prescriber’s schedule.

The most serious adverse reactions include severe hypotension, syncope, and rare cases of methemoglobinemia or allergic skin reactions such as necrosis. Patients should be monitored for sudden drops in blood pressure, dizziness, or signs of an allergic response, and the patch should be removed immediately if serious symptoms develop.

Minitran is contraindicated in patients with known hypersensitivity to glyceryl trinitrate or other organic nitrates, those with severe anemia, increased intracranial pressure, or uncompensated heart failure. It should also be avoided in individuals who have recently used phosphodiesterase‑5 inhibitors, as the combination can cause dangerous hypotension.